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Abstract: It has been suggested that oral absorption of low-permeable P-glycoprotein (P-gp) 21 
substrates can be increased through saturation of P-gp. For BCS class IV drug substances, saturating 22 
P-gp is challenging due to low aqueous solubility. The present study investigated if the BCS IV drug 23 
substance etoposide could be solubilized to a concentration saturating P-gp after oral administration. 24 
A formulation consisting of 10% (w/v) of pluronic® F-127 and polyvinylpyrrolidone/vinyl acetate 25 
(PVP/VA), and 57% (v/v) ethanol enhanced etoposide’s solubility approximately 100 times (16 mg 26 
mL-1) compared to its aqueous solubility. In vitro, this formulation was stable upon dilution in 27 
simulated intestinal fluid. In male Sprague-Dawley rats, oral administration of increasing solubilized 28 
etoposide doses using the formulation matrix increased the AUC0-∞ of etoposide dose-proportionally 29 
but resulted in a lower absolute oral bioavailability (F) and rate of absorption as compared to control. 30 
At the highest investigated dose (100 mg kg-1), AUC0-∞ and Cmax were significantly increased by 2.9- 31 
and 1.4-fold, respectively, compared to control dosed at 20 mg kg-1. A single oral dose of 20 mg kg-32 
1 zosuquidar followed by 20 mg kg-1 oral etoposide increased F 8.6-fold. In conclusion, a stable 33 
formulation with improved etoposide solubility was developed, yet the formulation did not result in 34 
increased oral bioavailability of etoposide. 35 
 36 








1. Introduction:  43 
P-glycoprotein (P-gp, MDR1) has been shown to limit the intestinal absorptive permeability of low-44 
permeable substrates in cell cultures (Alsenz et al., 1998; Collett et al., 1999; Sparreboom et al., 1997; 45 
Terao et al., 1996; Troutman and Thakker, 2003b). In vivo, in wild type (WT) rats, P-gp restricts the 46 
oral bioavailability of several P-gp substrates such as loperamide (Zamek-Gliszczynski et al., 2012), 47 
paclitaxel (Zamek-Gliszczynski et al., 2012), digoxin (Nielsen et al., 2016), and etoposide (Al-Ali et 48 
al., 2018a). This is evident since the oral bioavailability is significantly increased in mdr1a deficient 49 
rats (Al-Ali et al., 2018a; Nielsen et al., 2016; Zamek-Gliszczynski et al., 2012). Moreover, co-50 
administration of P-gp substrates with potent small-molecular P-gp inhibitors such as verapamil 51 
(Tsuruo et al., 1981), dexverapamil (Gramatté and Oertel, 1999), valspodar (PSC-833) (Mayer et al., 52 
1997; vanAsperen et al., 1997), or zosuquidar (LY335979) (Bardelmeijer et al., 2004) increased the 53 
oral bioavailability of the substrates in preclinical studies. However, using inhibitors to increase the 54 
oral bioavailability of P-gp substrates in some cases also affects metabolism via the cytochrome 55 
P450s and results in adverse effects (Breedveld et al., 2006; Palmeira et al., 2012; Varma et al., 2003; 56 
Varma and Panchagnula, 2005). Other studies have shown that co-administration of pharmaceutical 57 
excipients such as nonionic surfactants may also have the potential to increase the oral bioavailability 58 
of digoxin (Cornaire et al., 2004; Nielsen et al., 2016; Zhang et al., 2003), etoposide (Akhtar et al., 59 
2017; Al-Ali et al., 2018a), and paclitaxel (Varma and Panchagnula, 2005) in WT rats. To overcome 60 
the cellular efflux mediated by P-gp to increase intestinal absorption, it should in theory be possible 61 
to saturate the transporters by achieving intestinal concentrations well above the Km-value for the 62 
substrate-transporter binding as mentioned by e.g. Lin and Yamazaki (Lin and Yamazaki, 2003). 63 
Taking into consideration the degree of passive diffusion, intestinal metabolism, and P-gp substrate 64 
binding affinity, this may be a feasible strategy for drug substances with sufficient aqueous solubility, 65 
low passive diffusion, and limited metabolism. The experimental evidence for the feasibility of 66 
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saturating P-gp in the intestine through a pharmaceutical formulation strategy is however relatively 67 
limited and ambiguous. Lin and Yamazaki and Chiou et al., retrospectively, interpreted the 68 
pharmacokinetic human studies of the BCS II compound talinolol made by de Mey et al., and 69 
concluded that since the dose normalized AUC values after oral administration of increasing talinolol 70 
doses increased with higher doses, this suggested saturation of P-gp efflux (Chiou et al., 2001; de 71 
Mey et al., 1995; Lin and Yamazaki, 2003). Talinolol is also a substrate of absorptive solute carriers 72 
including organic anion transporting polypeptide 1A2 (OATP1A2) and OATP2B1 (Shirasaka et al., 73 
2010) making the absorption kinetics quite complicated.   74 
Since high doses of a P-gp substrate are needed to saturate the transporter, and as most P-gp substrates 75 
are poorly water-soluble substances (Wang et al., 2001), suitable pharmaceutical formulation 76 
approaches are required to solubilize the substrate. SMEEDs formulations could be used, but they 77 
often contain surfactants that are also P-gp inhibitors see e.g. Zhao et al. (Zhao et al., 2013). Thus, in 78 
the present study a formulation that can maintain the substrate in a solubilized-form upon dilution in 79 
the intestinal lumen without P-gp inhibiting surfactants was developed using etoposide a BCS class 80 
IV P-gp substrate. Etoposide was selected since intestinal P-gp limited oral etoposide bioavailability 81 
in WT rats, whereas etoposide was completely absorbed in mdr1a deficient rats (Al-Ali et al., 2018a). 82 
Moreover, data suggests that Bcrp has very little impact on the intestinal absorption of etoposide in 83 
mice (Allen et al., 2003).  A formulation was designed with ethanol and surfactant to enhance the 84 
solubility of etoposide. Etoposide has a low aqueous solubility of 0.15-0.2 mg mL-1 (Beig et al., 2015; 85 
Darwish et al., 1989) and since 10% ethanol significantly enhanced etoposide stability in artificial 86 
intestinal fluid, ethanol was used as a solubilizing co-solvent for etoposide (Joel et al., 1995). Since 87 
many nonionic surfactants inhibit P-gp in vitro (Al-Ali et al., 2019; Al-Ali et al., 2018b; Batrakova 88 
et al., 1999; Batrakova et al., 2003; Gurjar et al., 2018; Li-Blatter et al., 2012; Lo, 2003; Zhao et al., 89 
2016) and in vivo (Akhtar et al., 2017; Al-Ali et al., 2018a; Ma et al., 2011; Nielsen et al., 2016; Zhao 90 
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et al., 2013), a surfactant without P-gp inhibiting properties was chosen to evaluate the effect of 91 
increasing the dose of etoposide without a potential surfactant mediated P-gp inhibitory effect. 92 
Previous in vitro studies have reported that pluronic® F-127 did not inhibit the P-gp-mediated efflux 93 
of several substrates e.g. rhodamine 123 (Al-Ali et al., 2019; Batrakova et al., 2003; Wei et al., 2013), 94 
nelfinavir (Shaik et al., 2008), digoxin (Gurjar et al., 2018), and etoposide (Al-Ali et al., 2018a), 95 
hence this surfactant was chosen. Polyvinylpyrrolidone-vinyl acetate (PVP/VA) was suggested as a 96 
potential precipitation inhibitor (Kalaiselvan et al., 2006; Knopp et al., 2016; Xu and Dai, 2013) and 97 
formulation stabilizer during storage (Knopp et al., 2016; Prudic et al., 2014), thus it was included in 98 
the formulation. 99 
The aim of the present study was to prepare an oral formulation of high concentration of etoposide 100 
and to investigate the stability on storage, and upon dilution in fasted state simulated intestinal fluid 101 
(FaSSIF). Furthermore, the formulation was used to investigate if the systemic exposure of orally 102 
administered etoposide in rats could be increased through saturation of P-gp transport activity.  103 
 104 
2. Material and methods:  105 
2.1. Materials 106 
Caco-2 cells were obtained from the American Type Culture Collection (ATCC). Cell culture media 107 
and Hanks balanced salt solution (HBSS) were obtained from Life Technologies (Høje-Taastrup, 108 
Denmark). Etoposide (>99% purity) was purchased from Selleckchem (Munich, Germany). Sodium 109 
chloride, sodium taurocholate, sodium hydroxide, potassium chloride, L-α-phosphatidylcholine 110 
(approx. 60%), potassium phosphate monobasic (≥97%), and pluronic® F-127 suitable for cell 111 
culture, 2-(N-morpholino) ethane sulfonic acid (MES), N-[2-Hydroxyethyl] piperazine N’-[2-112 
ethanesulfonate] (HEPES), verapamil, digoxin, and bovine serum albumin (BSA) were from Sigma 113 
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(Brøndby, Denmark). Ethanol (99.5 %) was from VWR Chemicals (Fontenay-sous-Bois, France).  114 
Polyvinylpyrrolidone-vinyl acetate (Kollidon® VA 64, referred as PVP/VA) meets Ph. Eur. standards 115 
and was from BASF SE (Ludwigshafen, Germany). Transwell® inserts with polycarbonate membrane 116 
(0.4 μm pore size, 1.12 cm2) were from Corning Life Sciences and purchased through Sigma Aldrich 117 
(Brøndby, Denmark). Whatman® Nuclepore™ Track-Etched Membranes (0.03 µm pore-size, 19 mm 118 
in diameter) were purchased from Sigma Aldrich (Brøndby, Denmark). LOCTITE® 401 glue was 119 
purchased from RS Components Ltd. (Corby, UK). 3H-etoposide (specific activity 700 mCi mmol-1) 120 
was from Moravek (CA, USA). 14C-glycine (specific activity 87 mCi mmol-1) was purchased from 121 
Larodan (Solna, Sweden) and 14C-mannitol with a specific activity of 51.50 mCi/mmol was from 122 
Sigma Aldrich (Brøndby, Denmark). Ultima Gold liquid was purchased from Perkin Elmer 123 
(Skovlunde, Denmark). The radio-chemical purity of the isotopes was greater than 97%. 124 
 125 
2.2. Cell culture and transport experiments 126 
Caco-2 cells were cultured as previously described by Nielsen and co-workers (Nielsen et al., 2001). 127 
Briefly, cells were seeded in culture flasks and passaged in Dulbecco’s Modified Eagle’s medium 128 
(DMEM) supplemented with 10 % fetal bovine serum, penicillin/streptomycin (100 U ml-1 and 100 129 
µg ml-1, respectively), 1 % L-glutamine, and 1 % non-essential amino acids. Cells were seeded onto 130 
tissue culture treated Transwells (1.0 cm2, 0.4 µm pore size) at a density of 105 cells cm-2. 131 
Transepithelial electrical resistance (TEER) at room temperature was measured before the 132 
experiment. All TEER values of monolayers used were >400 Ω cm2. Transport experiments were 133 
performed on day 24-28 after seeding. 134 
Apical (A) to basolateral (B) and B to A fluxes of tritium labeled etoposide was measured in 10 mM 135 
HEPES buffers adjusted to pH 7.4. The concentration of etoposide on the donor (cis) side was 20 – 136 
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520 μM. Samples (20 µl) were taken from the donor solution at t=0 and 210 min and 150 µl samples 137 
were taken from the receiver solution and replaced with fresh buffer (t=30, 60, 90, 120, 150, 180, and 138 
210 min). The transport of 3H-etoposide was also measured in the presence of 100 µM of digoxin and 139 
50 μM verapamil on both donor and receiver side, respectively. Samples were transferred to 140 
scintillation vials, where 2 ml of scintillation fluid was added and the radioactivity was counted in a 141 
liquid scintillation analyzer. Fluxes were constant after 60 min. The steady state flux values were thus 142 
obtained as the means of the flux values between 90-210 min. After the experiment, the integrity of 143 
the Caco-2 cell monolayers was evaluated by 14C-mannitol transport studies. Samples were taken 144 
from the donor chamber (10 µl) at 20, 40, and 60 min, and from the receiver chamber at 0, 20, 40, 145 
and 60 min. The permeability (Papp) of mannitol was unaffected by etoposide, digoxin and verapamil 146 
and had a Papp value of 1.4 10
-06 ± 4.2 10-07 cm s-1. The transport across the filter without Caco-2 cells 147 
was investigated in order to assess whether the filter was a barrier to diffusion of etoposide. The 148 
permeability across the filter was calculated using non-steady state kinetics and had a value of 3.1 10-149 
04 ± 4.2 10-05 cm s-1. 150 
The P-gp dependent flux (JP-gp) was calculated similarly to described by Troutman and Thakker 151 
(Troutman and Thakker, 2003a), where the total flux of etoposide was subtracted with the flux of 152 
etoposide in the presence of 100 µM of digoxin and 50 μM verapamil to yield the concentration 153 
dependent effect of P-gp on etoposide transport. Here we used Caco-2 cells from ATCC, and 154 
proteomics data suggest that BCRP expression is very low in the substrain compared to Caco-2 cells 155 
obtained from The European Collection of Authenticated Cell Cultures (ECACC) or/and Deutsche 156 
Sammlung von Mikroorganismen und Zellkulturen (DSMZ), as reviewed in Al-Ali et al., 2019 (Al-157 
Ali et al., 2019). In Caco-2 cells from DSMZ it has been shown that 25 µM zosuquidar abolish 158 
polarized etoposide transport completely (Nielsen et al., 2020), while it has also been shown that 159 
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verapamil completely abolishes polarized etoposide in Caco-2 cells (Mo et al., 2011). Therefore, it 160 
seems likely that in Caco-2 cells from ATCC BCRP has a minor impact on etoposide transport.  161 
The resulting etoposide flux in the B-A direction was then fitted to the following equation: 162 




    (1) 164 
where, JP-gp is the P-gp mediated flux, JP-gp,max is the maximal flux, Km,app is the apparent Michaelis 165 
constant and Cd is the donor concentration. 166 
 167 
2.3. Animals  168 
In vivo pharmacokinetic studies were performed in WT male Sprague-Dawley rats, which were from 169 
Charles River Laboratories (Sulzfeld, Germany). The study protocol was approved by the local ethical 170 
committee in accordance with EC Directive 2010/63/EU and Belgian Law/1991 for Protection of 171 
Vertebrate Animals used for Experimental and other Scientific Purposes. The rats were received one 172 
week prior to the in vivo experiments, acclimatized and maintained on standard feed conditions with 173 
free access to water. The animals were fasted for 16 h before the pharmacokinetic studies. During the 174 
experiments, the rats had free access to water, but not food. At the day of the experiment, the weight 175 
of the animals was 242-275 g.  176 
 177 
2.4. Preparation of etoposide-containing formulations  178 
Different formulations of etoposide were prepared using the nonionic surfactant pluronic® F-127, the 179 
copolymer PVP/VA, ethanol, and ultra-purified water (Table 1). Pluronic® F-127 was first dissolved 180 
in 57% (v/v) ethanol solution at room temperature. Etoposide was then added to the surfactant-181 
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containing solution and placed in a water bath at 40o C for 15-30 min, before the solution was mixed 182 
using a magnetic stirrer for 15-30 min. The solution was visually inspected for undissolved particles. 183 
PVP/VA powder was subsequently added, and the mixture placed in a water bath at 37o C for 15-30 184 
min, before being mixed using a magnetic stirrer for 15-30 min. The solution was again visually 185 
investigated for undissolved particles. Finally, provided that the etoposide-containing formulation 186 
was clear, the formulation was transferred to a glass container, protected from light, and kept at room 187 
temperature overnight (approx. 15 h). If no sign of precipitation appeared after 15 h, the formulation 188 
was further investigated for precipitation upon dilution with FaSSIF, see details below.  189 
 190 
2.5. Monitoring of etoposide containing-formulations diluted with fasted state simulated 191 
intestinal fluid  192 
Monitoring that etoposide does not precipitate in the different formulations when diluted with FaSSIF 193 
was investigated as previously described by Al-Ali et al. (Al-Ali et al., 2018a). Briefly, FaSSIF was 194 
prepared according to Galia et al., composed of 0.39 g potassium phosphate monobasic, 0.77 g 195 
potassium chloride, 3 mM sodium taurocholate, 0.75 mM L-α-phosphatidylcholine, and ultra-purified 196 
water added to 100 mL (Galia et al., 1998). The pH was then adjusted to 6.50 ± 0.05 with sodium 197 
hydroxide before the osmolality was adjusted to 270 ± 10 mOsm kg−1 using sodium chloride (Galia 198 
et al., 1998). The different formulations of etoposide were then added to FaSSIF in a ratio of 1:2 199 
(formulation:FaSSIF) to simulate the likely intestinal dilution in the rats (McConnell et al., 2008) and 200 
monitored for two hours by measuring the absorbance at 400 nm and 25o C every 10 min using a UV-201 
spectrophotometer (Genesys 10-S from Thermo Fisher Scientific (WI, USA)). Before each 202 




2.6. Dialysis studies investigating etoposide release from different formulations   205 
Dialysis studies were designed and optimized as previously described by Al-Ali et al. (Al-Ali et al., 206 
2018a), with minor modifications. In brief, the dialysis setup allows the diffusion of free-fraction of 207 
etoposide (unbound to micelles) and retains etoposide-bound to micelles, which should be not 208 
diffused across a 0.03 μm pore-size polycarbonate membrane during the course of the experiment (2 209 
h). Polycarbonate membranes (0.03 μm pore size, 19 mm in diameter) were attached to Transwell 210 
holders (1.12 cm2) by LOCTITE® 401 glue and left to dry at room temperature overnight (Al-Ali et 211 
al., 2018a). The Transwell inserts, with attached polycarbonate membranes, were then hydrated 212 
overnight in ultra-purified water. On the day of the experiment, Transwell inserts with polycarbonate 213 
membranes were first pre-incubated with HBSS supplemented with 10 mM HEPES and adjusted to 214 
pH 7.40 ± 0.05 (HBSS+) on a shaking plate at 220 rpm at 37° C for 10 min. Donor solutions of 3H-215 
etoposide and 14C-glycine were prepared in HBSS+ (Control), or in different formulation-matrices 216 
containing 10% (w/v) PVP/VA, 57% (v/v) ethanol, and pluronic® F-127 at 1.5, 3 or 10%, referred to 217 
as Matrix-PF127 1.5%, Matrix-PF127 3%, or Matrix-PF127 10%, respectively, or mixed with a 218 
formulation with the highest concentration of etoposide. This formulation contained 15-16 mg mL-1 219 
etoposide, 10% (w/v) of pluronic® F-127 and PVP/VA, and 57% (v/v) ethanol. The solution 220 
containing radioactive compounds was then added to FaSSIF at a 1:2 ratio to achieve final 221 
concentrations of 3H-etoposide and 14C-glycine at 0.25 µCi mL-1, 0.36 µM and 0.25 µCi mL-1, 2.87 222 
µM, respectively, before these isotopes-containing solutions (500 μL) were added to the upper side 223 
of the polycarbonate membrane. Experiments started when receiver-release media (1650 μL) was 224 
loaded in the lower side of the polycarbonate membrane. Receiver-release media consisted of HBSS 225 
buffer supplemented with 10 mM HEPES and adjusted to pH 6.50 ± 0.05 for all conditions except 226 
for the formulation containing the highest concentration of etoposide where the medium was the 227 
matrix of this formulation (i.e. 10% of pluronic® F-127 and PVP/VA, and 57% ethanol without 228 
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etoposide) in order to prevent etoposide precipitation when accumulated in the receiver chamber. 229 
Experiments were performed at 37° C and shaking mode 220 rpm. Donor samples were collected at 230 
0, 60 and 120 min, while receiver samples were collected at 15, 30, 60, 90, and 120 min. Receiver-231 
release medium was replaced at each sampling occasion in order to preserve the sink condition. 232 
Finally, Ultima Gold scintillation fluid (2 mL) was added to every sample, vortexed for one minute 233 
and counted for 10 min on a scintillation counter (TriCarb 4910TR) from Perkin Elmer, USA. 234 
 235 
2.7. Pharmacokinetic study in wild-type male Sprague-Dawley rats 236 
The rats were randomly assigned to receive different doses of etoposide in ethanol solution or in a 237 
formulation matrix consisting of 10% (w/v) pluronic® F-127 and PVP/VA, 57% (v/v) ethanol, and 238 
ultra-purified water. For intravenous administration, the rats received etoposide solution (2.86 mg 239 
mL-1 in 57% v/v ethanol) at a dose of 5 mg kg-1 etoposide. Administration volume was adjusted to 2 240 
mL with water before dosing the rats. For oral administration by oral gavage, the control group 241 
received an etoposide solution (2.86 mg mL-1 in 57% v/v ethanol) at a dose of 20 mg kg-1 etoposide 242 
and a dosing volume of 7 mL kg-1. In the positive control group, the rats received a zosuquidar 243 
solution (2 mg mL-1) at a dose of 20 mg kg-1 and dosing volume of 10 mL kg-1, 30 min before the 244 
administration of etoposide doses which were administered in a similar fashion to the control group. 245 
For oral administration of increasing doses of etoposide, an increasing concentration of etoposide was 246 
solubilized in the formulation matrix i.e. 2.86, 7.15 and 14.3 mg mL-1. These etoposide-containing 247 
formulations were administered at doses of 20, 50, and 100 mg kg-1, respectively, in a dosing volume 248 
of 7 mL kg-1. Each dosing group consisted of 5-6 male Sprague-Dawley rats. After oral or intravenous 249 
administration of etoposide, blood samples were collected at 0.25, 0.5, 0.75, 1, 2, 3, 4, and 6 h, as 250 
well as at 5 min (0.0833 h) post intravenous administration of etoposide. The samples were obtained 251 
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at each sampling point by puncturing the lateral tail vein using a 23G needle and approximately 35 252 
μL of blood were collected using a capillary tube from VITREX Medical A/S (Herlev, Denmark). 253 
The capillaries with samples were then sealed with VITREX Sigillum Wax. Plasma samples were 254 
harvested immediately from these capillaries after centrifugation at 1900xg for 10 min at 4o C and 255 
transferred to a 10 µL end-to-end capillary (VITREX) followed by storage at -20° C until further 256 
bioanalysis. At 6 h, the last samples were collected, and the animals were euthanized.  257 
 258 
2.8. Quantification of etoposide in pharmacokinetic studies  259 
Quantification of etoposide in plasma samples was performed on an API 4000™ LC/MSMS System 260 
from AB SCIEX (Ontario, Canada). Briefly, plasma samples were precipitated with acetonitrile after 261 
wash-out from the end-to-end capillaries. Chromatographic separation was carried out using an 262 
Acquity UPLC BEH C18 column (1.7 μm, 2.1 mm × 50 mm). Gradient elution was performed at 50 263 
°C with 0.01M ammonium acetate (mobile phase A) and acetonitrile (mobile phase B). Starting 264 
conditions were 5 % B for 0.25 minutes, then a linear gradient to 95% B was applied over 1.25 265 
minutes, followed by an isocratic hold at 95% B for 0.5 min before re-equilibration at 5% B. Total 266 
run time was 2.5 min and a flow rate of 0.6 mL/min was applied.  267 
The LC-MS/MS was operated in positive ion mode using the TurboIonSprayTM-interface 268 
(electrospray ionization), and was optimized for the quantification of etoposide, applying multiple 269 
reaction monitoring (m/z 587.2 →  m/z 381).  270 
Incurred samples were quantified against calibration curves prepared in blank rat plasma. Independent 271 
quality control samples were included to evaluate accuracy (between 80 and 120% of the nominal 272 
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value) of the analytical run. The concentrations were correlated linearly, with a 1/x^2 weighing, with 273 
the MS response between 1.00 and 10000 ng mL-1. 274 
 275 
2.9. Population Pharmacokinetic analysis 276 
Population pharmacokinetic analysis was performed using Monolix 2018R2 (Lixoft SAS, Antony, 277 
France) based on a two-compartment population pharmacokinetic model with linear first order 278 
elimination and an oral depot compartment with subsequent first order absorption. Population 279 
pharmacokinetic parameter estimates were generated using the stochastic approximation expectation-280 
maximization (SAEM) algorithm. Modeling was performed using the clearance parameterization 281 
assuming a lognormal distribution of individual parameters. The individual parameter estimates for 282 
the ith subject were modeled according to equation 2.  283 
𝜃𝑖 = 𝜃pop ⋅ 𝑒
𝜂𝜃,𝑖                (2) 284 
where 𝜃𝑖 is the individual parameter estimate for the ith subject, 𝜃pop is the typical population 285 
parameter estimate and 𝜂𝜃,𝑖 is assumed to be the random individual deviation for the ith subject for a 286 
particular population parameter 𝜃. The clearance parametrization included the volume of the central 287 
compartment (V1), the elimination clearance (CL), the volume of the peripheral compartment (V2), 288 
and the inter-compartmental flow between the central and the peripheral compartment (Q2). Oral 289 
administration was modeled using a dosing compartment and subsequent first order absorption. The 290 
final model included covariate effects, which partly explained differences observed between animals 291 
assigned to the different formulation groups. Forward inclusion of covariates was judged based on 292 
the decrease in objective function value expressed as -2 log likelihood (-2LL) and Akaike’s 293 
information criterion (AIC). Covariate selection was guided by physiological plausibility and 294 
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statistical significance (P < 0.05). Covariate effects of the final population model included the 295 
presence of zosuquidar on F and the presence of experimental matrix (referred as formulation G-296 
matrix) on F and ka. The final model estimated inter-individual variability for F, ka, V1 and CL. 297 
Residual error was accounted for by a combined (additive and proportional) error model (Equation 298 
3).   299 
log(𝑌𝑖𝑗) = log(𝑐pred,𝑖𝑗) + (𝑎 + 𝑏 ⋅ log(𝑐pred,𝑖𝑗))𝜖𝑖𝑗            (3) 300 
where the jth observation of the ith subject deviates from the jth prediction of the ith subject, cpred,ij, 301 
by an additive term, a, and a proportional term, b. 𝜖𝑖𝑗 was assumed to be the random variable for the 302 
𝑗th concentration of the 𝑖th individual, sampled from a distribution with zero as a mean and a variance 303 
of 𝜎2. Individual Bayesian estimates were used to calculate mean AUC0-∞ per study cohort. Individual 304 




           (4) 306 
 307 
2.10. Statistics  308 
The results of in vitro studies were obtained from at least three experiments and presented as mean 309 
values ± SEM. Caco-2 cell experiments were conducted in three independent cell passages and values 310 
are presented as mean values ± SEM. The results of the in vivo pharmacokinetic studies were obtained 311 
from 5 or 6 rats per study cohort and data are presented as mean values ± SEM. Statistical analysis 312 
was performed using GraphPad Prism 7.01 from GraphPad Software, LLC (San Diego, CA, USA). 313 
One-way ANOVA test followed by Tukey’s multiple comparisons test were selected for multiple 314 
comparisons. P value < 0.05 was considered statistically significantly different from control. 315 
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Moreover, dose-proportionality has been assessed by plotting AUC0-∞ as a function of oral etoposide 316 
doses and linear regression analysis was performed. 317 
 318 
3. Results 319 
3.1. Transepithelial flux of etoposide across Caco-2 cells 320 
Etoposide transport across Caco-2 monolayers was investigated, and in the following Figure 1, the 321 
A-B and B-A flux dependent on P-gp is shown. The A-B flux dependent on P-gp shows a gradual 322 
increase as a function of concentration and at higher concentrations the flux is relatively linear as a 323 
function of concentration in the apical donor solution (Fig. 1A). In the B-A direction, the flux of 324 
etoposide across Caco-2 cells monolayers can be described by Michaelis-Menten like kinetics where 325 
the flux becomes saturated with increasing concentration in the basolateral medium. The resulting 326 
kinetical parameters were estimated at 257 ± 32 µM, 199 ± 17 pmol cm-2 min-1, and 1.7 ± 0.2 for 327 
Km,app, JP-gp, max, and the Hill coefficient, respectively. 328 
 329 
3.2. Etoposide did not precipitate in formulations containing high percentages of ethanol  330 
Different formulations of etoposide were prepared using 44% or 57% (v/v) ethanol, 2-10% (w/v) 331 
pluronic® F-127, and 0-15% (w/v) PVP/VA (Table 1). Etoposide in formulations containing 44% 332 
(v/v) ethanol either contained low concentration of etoposide such as 9 mg mL-1 (Formulation A), 333 
which was not sufficient to perform our study or precipitated after overnight incubation such as 334 
Formulation B (Fig. 2). Etoposide formulations (C-G) showed no signs of etoposide precipitation 335 
after overnight incubation; e.g. Formulation G as shown in Figure 2. Etoposide solubility in these 336 
formulations containing 57% (v/v) ethanol was higher than in formulation A and B. Formulation D 337 
showed that 6% (w/v) of the surfactant was required to dissolve 15 mg mL-1 etoposide in PVP/VA-338 
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free formulation. Formulations A, C, and E-G were designed to contain 5-15% (w/v) PVP/VA as a 339 
potential precipitation inhibitor. Formulation G consisting of 10% (w/v) of pluronic® F-127 and 340 
PVP/VA, 57% ethanol, and water could solubilize an amount of etoposide corresponding to a 100-341 
fold increase compared to the aqueous solubility. Further studies were conducted to investigate 342 
whether etoposide precipitates after the addition of different formulations to FaSSIF.  343 
 344 
3.3. Etoposide did not precipitate from Formulation G after dilution in fasted state simulated 345 
intestinal fluid 346 
Formulations C-E showed a fast etoposide precipitation (less than 30 min) after dilution in FaSSIF. 347 
Formulation F started to precipitate after approx. one hour and reached similar levels of absorbance 348 
values as C-E at 90 min. Therefore, formulations C-F were only prepared and investigated once. 349 
Formulation G showed no sign of etoposide precipitation for 120 min (Fig. 3). After 120 min, 350 
etoposide started to precipitate indicating that the matrix of formulation G was able to maintain 351 
etoposide in a solubilized form in FaSSIF for two hours (Fig. 3), which is the period that likely covers 352 
the absorption phase of etoposide in rats. Equal amounts of pluronic® F-127 and PVP/VA at 10% 353 
(w/v) were required to maintain etoposide in a solubilized form when diluted with FaSSIF. Among 354 
the investigated formulations, formulation G was stable in FaSSIF and the next step was to investigate 355 
if the formulation G would retain etoposide.  356 
 357 
3.4. Etoposide release was similar from different surfactant-containing solutions and matrix of 358 
formulation G  359 
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As shown in Figure 4, simultaneous etoposide and glycine release from different pluronic® F-127-360 
containing solutions and formulation G to receiver-release media increased time dependently. The 361 
release of etoposide and glycine from different pluronic® F-127-containing formulations and from 362 
formulation G was similar to the release in the control buffer i.e. without surfactant. Moreover, there 363 
was no statistically significant difference between the slopes of the time-dependent release of 364 
etoposide or glycine compared to control. The presence of non-radiolabeled etoposide in formulation 365 
G did not affect the release of radiolabeled etoposide during the course of the experiment.  366 
 367 
3.5. Etoposide population pharmacokinetics in WT male Sprague-Dawley rats after intravenous 368 
and oral administration  369 
Pharmacokinetic data available included 321 concentration-time points collected from 35 male WT 370 
Sprague-Dawley rats. The PK profile af intravenous administration of etoposide is shown in figure 5, 371 
illustrating a fast distribution phase followed by a slower elimination phase. Data points at 4 h post 372 
intravenous administration of etoposide are not shown in Figure 5 as the plasma concentration values 373 
were below the limit of quantification (LOQ) at this time point, and only three plasma-concentrations 374 
had values above LOQ at 6 h. Etoposide pharmacokinetic profiles after oral administration of 375 
etoposide-containing solutions were best described by a two-compartment structural model with 376 
linear elimination and first-order absorption (Fig. 6). Subsequently, a covariate model was developed 377 
to account for the inter-individual variability arising from the experimental design. The introduction 378 
of zosuquidar dose as a covariate on the oral bioavailability F, and matrix-G presence as a covariate 379 
on F as well as on the absorption rate constant (ka) significantly improved the model fit. After 380 
covariate inclusion, the unexplained inter-individual variability for F and ka, calculated as the square 381 
root of the exponential variance of 𝜂 minus 1, decreased from 153% for F and 59.7% for ka to 15.9% 382 
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and 53.5%, respectively, from the base structural model to the final covariate model (Δ138% for F 383 
and Δ6.15% for ka). Estimated population pharmacokinetic parameters, precision of the parameter 384 
estimates and objective function values of both the base structural model and the final covariate model 385 
are presented in Table 2. Empirical Bayesian estimates were used to calculate AUC0-∞ and dose 386 
normalized AUC0-∞. AUC0-∞, dose normalized AUC0-∞, t½, tmax and Cmax are presented in Table 3. 387 
Rats pretreated with zosuquidar showed the largest etoposide exposure (AUC0-∞ of 4511 ng h mL
-1 388 
kg). Dose-proportional etoposide exposure was observed for the 20, 50, and 100 mg kg-1 dosing 389 
cohorts receiving etoposide prepared in the matrix of formulation G (i.e. 10% of pluronic® F-127 and 390 
PVP/VA, 57% ethanol, and water), and R square was equal to 0.99 when the AUC was plotted as a 391 
function of dose (supplementary figure S1). However, the F, ka, AUC0-∞, and Cmax were significantly 392 
lower when the rats were dosed with etoposide 20 mg kg-1 dissolved in the matrix of formulation G 393 
compared to the control group. Etoposide oral bioavailability significantly increased when the rats 394 
were pretreated with zosuquidar. The oral pharmacokinetic profile showed that the oral absorption of 395 
etoposide was slower in matrix-based formulations as was also apparent from the decreased ka values.   396 
 397 
4. Discussion 398 
In the present study, a stable formulation containing high concentration of etoposide and ethanol 399 
(57%) was developed using a surfactant without P-gp inhibiting properties. After oral administration 400 
of etoposide in this formulation, no increased bioavailability related to P-gp saturation could be 401 
shown, illustrating the practical difficulties in saturating P-gp mediated transport of low soluble drug 402 
substances for increasing the oral absorption through a formulation approach.   403 
To investigated if the transport of etoposide was saturable, we used the approach described by 404 
Troutman and Thakker (Troutman and Thakker, 2003a), in which the net flux due to P-gp mediated 405 
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transport is estimated by subtracting the flux under P-gp inhibited conditions. We found that the B-A 406 
transport was saturable with kinetical parameters similar to the ones described by Troutman and 407 
Thakker in Caco-2 cells, for Km,app 257 vs. 461 µM, and for Jmax 199 vs. 354 pmol cm
-2 min-1 408 
(Troutman and Thakker, 2003a). Makhey et al. found a similar Km value of 113 µM in Caco-2 cells 409 
and 94-119 µM in stripped rat intestinal tissue (Makhey et al., 1998). Troutman and Thakker 410 
estimated a higher Km value of 1360 µM for the A-B transport direction (Troutman and Thakker, 411 
2003a), however this value was outside the concentration range that could be investigated in our set-412 
up. Even though the B-A transport appears saturable and while it is more difficult to be assessed from 413 
the A-B transport, studies in wild-type and knock-out rats clearly show that the apically located P-gp 414 
is highly attenuating the oral etoposide absorption (Al-Ali et al., 2018a). Considering the above 415 
mentioned Km values, generally of approximately 100-500 µM, an intestinal concentration of 10 times 416 
these values would likely be required to fully saturate P-gp mediated transport by etoposide itself, 417 
corresponding to approximately 5000 µM for the worst case scenario. A solubility higher than that 418 
could be achieved with formulation G (16 mg mL-1 (27183 µM)) containing 10% of pluronic® F-127 419 
and 10% PVP/VA. 16 mg ml-1 is approximately 100-fold higher than the aqueous solubility of 420 
etoposide (Beig et al., 2015; Darwish et al., 1989). Pluronic® F-127 forms micelles that have the 421 
capacity to solubilize lipophilic drug substances e.g. meso-tetraphenyl porphine (mTPP) (Sezgin et 422 
al., 2007), rofecoxib (Ahuja et al., 2007), ibuprofen (Wan et al., 2010), paclitaxel, and lapatinib 423 
(Kelishady et al., 2015). The reported critical micelle concentration (CMC) values of pluronic® F-424 
127 were 1, 0.1, and 0.025% (w/v) at 25, 30, and 35o C (Alexandridis and Hatton, 1995), respectively. 425 
Etoposide in micelles could be retained from permeation and hence the oral absorption could be 426 
decreased, which has been reported with 25% polysorbate 20 (Al-Ali et al., 2018a). However, the 427 
presence of different concentrations of pluronic® F-127 did not affect the in vitro release of etoposide 428 
and glycine compared to the release from a surfactant-free formulation. Similarly, 1% (w/v) pluronic® 429 
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F-127, which is above the CMC value, did not affect the release of the lipophilic drug rofecoxib 430 
(Ahuja et al., 2007) (Log P 2.56) (Chemicalize, 2018).  431 
 Previous pharmacokinetic studies in rats have shown that tmax of etoposide exposure was between 432 
0.25-1.75 h (Al-Ali et al., 2018a; Li et al., 2009; Zhao et al., 2013), therefore the formulation should 433 
maintain etoposide in its solubilized form for two hours when diluted in FaSSIF. This period was 434 
considered sufficient for further in vivo studies. In formulation G, solubilized etoposide did not 435 
precipitate for two hours when diluted with FaSSIF. Thus, pluronic® F-127 probably had two 436 
functions: i) enhanced the solubility of etoposide, and ii) decreased the precipitation rate of etoposide 437 
as it was also suggested by (Li et al., 2012; Xu and Dai, 2013), thereby stabilizing the formulation in 438 
FaSSIF. Importantly, it seems that a balance between pluronic® F-127 and PVP/VA concentrations 439 
(i.e. 10% of each) in the formulation was needed to achieve these formulation characteristics. Thus, 440 
if an intestinal dilution of 3-10 is expected after oral administration of a 16 mg mL-1 etoposide 441 
formulation, and initial estimated intestinal concentration of 2718 – 9061 µM could be obtained, 442 
which could be able to saturate P-gp assuming that etoposide remains in solution. 443 
In rats receiving 100 mg kg-1of etoposide in formulation G, a higher AUC0-∞ was obtained compared 444 
to rats receiving 20 mg kg-1 etoposide in a 57% ethanol solution. Even though the systemic exposure 445 
of etoposide increased with higher doses, the absolute bioavailability decreased, and this does not 446 
seem to involve P-gp saturation by etoposide as the absolute bioavailability should then increase. 447 
However, zosuquidar enhanced the oral absorption and bioavailability of etoposide. Yet, in the 448 
presence of 20 mg kg-1 zosuquidar, only 34.5% of the etoposide dose reached the systemic circulation, 449 
thus zosuquidar itself most likely did not cause full inhibition of intestinal P-gp. 450 
Surprisingly, the absolute oral bioavailability of etoposide was low compared to our previous study 451 
(Al-Ali et al., 2018a). Al-Ali and coworkers reported that the oral bioavailability of etoposide was 27 452 
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± 5% (Al-Ali et al., 2018a). Zhao and co-workers reported an oral bioavailability of etoposide of 25 453 
± 7% in WT male Sprague-Dawley rats dosed with 12 mg kg-1 etoposide suspended (1.5 mg mL-1) in 454 
0.5% sodium carboxymethyl cellulose (Zhao et al., 2013). Li and co-workers reported an oral 455 
bioavailability of 7.5 ± 1.8% in WT male Sprague-Dawley rats after oral administration of a 6 mg kg-456 
1 etoposide solution prepared as an injectable formulation (specific composition not specified) (Li et 457 
al., 2009). In the present study, it was not clear why the oral bioavailability of etoposide was low in 458 
the control group, however, besides the known variabilities observed between animal studies (Festing 459 
and Altman, 2002), one could speculate that the 57% of ethanol could be the cause, since etoposide 460 
could precipitate in the intestinal lumen. In the previous study by Al-Ali et al, the oral bioavailability 461 
of etoposide (27%) was obtained after administration of 20 mg kg-1 in 40% ethanol (2 mg ml-1) 462 
administered with a dosing volume of 10 mL kg-1 (Al-Ali et al., 2018a). In the present study an 463 
etoposide solution (2.86 mg mL-1) in 57% (v/v) ethanol at a dose of 20 mg kg-1 etoposide and a dosing 464 
volume of 7 mL kg-1 was used, thus approximately similar absolute amounts of ethanol were 465 
administered in the two studies, but the concentration of etoposide and the amount of water differ, 466 
with concentration of etoposide in the previous study being lower and water amount higher. This 467 
could affect the susceptibility of etoposide precipitation in the solution used here to be higher. Ethanol 468 
is rapidly absorbed in rats with a tmax less than 60 min and 50% disappearance of ethanol from the 469 
stomach after 60 min (Siegers et al., 1972). If etoposide has indeed precipitated, this could explain 470 
the low bioavailability. Population analysis indicated that formulation G decreased both the oral 471 
bioavailability and the absorption rate while a clear increase in oral bioavailability was quantified in 472 
the presence of zosuquidar administration. Introduction of these covariate effects on the respective 473 
parameters of the population pharmacokinetic model significantly decreased the objective function 474 
values (OFVs) and improved the model fit upon inspection of diagnostic plots (see Table 2). It has 475 
been described earlier that 25% (v/v) polysorbate 20 decreased etoposide oral absorption, when 476 
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similar doses of 20 mg kg-1 of etoposide were co-administered in rats (Al-Ali et al., 2018a). In the 477 
study reported by Al-Ali et al., dialysis experiments showed that polysorbate 20 at 25% (v/v) 478 
abolished etoposide release across polycarbonate membranes (Al-Ali et al., 2018a). In contrast, the 479 
present study showed that etoposide release from the matrix across polycarbonate membrane was not 480 
affected by the presence of different components in the formulation such as pluronic® F-127. In vivo, 481 
this points to an effect of the high ethanol concentration rather than incomplete release from colloidal 482 
structures present in the intestinal lumen.   483 
 484 
5. Conclusion  485 
In conclusion, an oral formulation of high-concentration of etoposide, which maintained etoposide in 486 
a solubilized form under short-term storage conditions and when diluted with simulated intestinal 487 
fluid was developed. Administration of increasing etoposide doses using this formulation-matrix 488 
enhanced the plasma exposure of etoposide dose-proportionally. However, the applied doses were 489 
not able to saturate P-gp, and the absolute absorption fraction decreased as a function of increasing 490 
dose. To saturate intestinal P-gp by etoposide in rats, oral formulations maintaining high 491 
concentrations of etoposide in solution are needed, yet the present study is a starting point for 492 
developing formulation approaches using other drug candidates aimed at increasing the oral 493 
absorption of P-gp substrates and illustrates the difficulties in developing formulations aimed at 494 
saturating intestinal P-gp transport. 495 
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 672 
Figures Legends:  673 
Figure 1. Transepithelial P-gp dependent flux of etoposide across Caco-2 cell monolayers. The 674 
steady-state P-gp dependent flux (pmol cm-2 min-1) of etoposide across Caco-2 cells grown on 675 
permeable support for 24-28 days was studied as a function of etoposide concentration (Cd, μM) in 676 
the donor solution. The A-B transport (A) and B-A (B) transport was measured in 3 cell passages. In 677 
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B, the line is obtained by fitting experimental points to Eq. 1 described in Materials and Methods.  678 
Values are given as mean ± SEM. 679 
 680 
Figure 2. Pictures of etoposide formulations after 15 hours of storage at room temperature. 681 
Formulation B contained 12 mg mL-1 etoposide, 10% (w/v) of pluronic® F-127 in 44% (v/v) ethanol. 682 
Formulation G contained 16 mg mL-1 etoposide, 10% (w/v) of pluronic® F-127, and 10% (w/v) of 683 
PVP/VA in 57% (v/v) ethanol.  684 
 685 
Figure 3. Absorbance measurments at 400 nm of etoposide formulations added to fasted state 686 
simulated intestinal fluid (FaSSIF) in a ratio of (Formulation:FaSSIF, 1:2) as a function of time. 687 
Etoposide formulations were composed as shown in Table 1. The measurments were performed at 688 
room temperature. For formulation G, n=4 and as mean ± SEM, for other formulations n=1. 689 
 690 
Figure 4. Time dependent release of etoposide and glycine from different formulations across 691 
0.03 μm polycarbonate membrane. Donor solutions of 3H-etoposide and 14C-glycine were prepared 692 
in Hanks Balanced Salt Solution (HBSS) buffer supplemented with 10 mM HEPES and adjusted to 693 
pH 7.40 ± 0.05 (Control), or in different formulation-matrix containing 10% (w/v) PVP/VA, 57% 694 
(v/v) ethanol, and pluronic® F-127 (PF127) at 1.5, 3, or 10% (w/v), referred as Matrix-PF127 1.5%, 695 
Matrix-PF127 3%, or Matrix-PF127 10%, respectively, or mixed with formulation G which contained 696 
15-16 mg mL-1 etoposide, 10% (w/v) of PF127 and PVP/VA, and 57% (v/v) ethanol. Receiver-release 697 
media were HBSS buffer supplemented with 10 mM HEPES and adjusted to pH 6.50 ± 0.05 for all 698 
conditions, except in formulation G condition where the receiver-release media was the matrix of 699 
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formulation G (i.e. 10% (w/v) of PF127 and PVP/VA, and 57% ethanol, and q.s. water but without 700 
etoposide). Experiments were performed at 37 °C and shaking mode 220 rpm. Data are expressed in 701 
mean ± SEM from 3-4 independent membranes and as one membrane per experiment. 702 
 703 
 704 
Figure 5. Plasma concentration time profile of etoposide after intravenous administration of 5 705 
mg kg-1 etoposide to wild-type male Sprague-Dawley rats. Each data point is shown as mean ± 706 
SEM from 3-6 rats. 707 
 708 
Figure 6. Plasma concentration time profiles of etoposide after oral administration of different 709 
doses of etoposide in wild-type male Sprague-Dawley rats. A) Etoposide was administered orally 710 
at a dose of 20 mg kg-1 in 57% (v/v) ethanol solution (Control), or at increasing doses of etoposide 711 
dissolved in matrix at 20, 50, and 100 mg kg-1 etoposide. The matrix was consisted of 10 % (w/v) 712 
pluronic® F-127 and PVP/VA, and 57% (v/v) ethanol, and q.s. water. At the highest oral dose, the 713 
formulation is referred as formulation G. B) Etoposide was administered orally as control after the 714 
rats were received an oral dose 20 mg kg-1 of zosuquidar. Each data point is shown as mean ± SEM 715 
from 5-6 rats. The solid lines are only connecting the data points.  716 
 717 
Supplementary Figure S1. AUC after oral administration as a function of dose.  718 





Table 1: Composition of oral formulations of etoposide. (nd : not determined, ✓: Yes, ÷ : no).  







Formulations                                                                     Function 
A B C D E F G                
Etoposide (mg mL-1) 9 12 12 15 15 15 16                  API, P-gp substrate 
Pluronic® F-127 (% w/v) 4.7 10 6 6 2 6 10                  Surfactant, precipitation inhibitora 
PVP/VA (% w/v) 5 - 15 - 5 10 10                  Precipitation inhibitor 
Ethanol (% v/v) 44 44 57 57 57 57 57                  Co-solvent/solvent 
Ultra-purified water qs qs qs qs qs qs Qs                 Solvent 
Stable under storage for 15 h ✓ ÷ ✓ ✓ ✓ ✓ ✓ 
Stable for 2 h after dilution  
with FaSSIF 
nd nd ÷ ÷ ÷ ÷ ✓ 
Table 2: Population pharmacokinetic parameter estimates of the base structural model and the 
final covariate model. Precision of the parameter estimates is reported as relative standard error 
(RSE%). F = oral bioavailability, ka = absorption rate, V1 = volume of the central compartment, V2 
= volume of the peripheral compartment, CL = elimination clearance, Q2 = intercompartmental 
clearance, 𝛽𝐹,𝐹𝑂𝑅𝑀 = categorical covariate effect of formulation G presence on F, 𝛽𝐹,𝑍𝑂𝑆𝑈 = 
categorical covariate effect of zosuquidar presence on F, 𝛽𝐾𝑎,𝐹𝑂𝑅𝑀 = categorical covariate effect of 
formulation G presence on ka, a = additive error model term, b = proportional error model term, OFV 






 Base structural model Final covariate model 
Fixed effects [RSE%] 
F (%) 6.76 [24.2] 3.92 [16.7] 
ka (h-1) 2.69 [13.1] 4.54 [20.2] 
V1 (L kg-1) 3.63 [18] 2.91 [18.7] 
V2 (L kg-1) 3.18 [12.2] 3.78 [17.9] 
CL (L h-1 kg -1) 1.61 [4.62] 1.55 [10.1] 
Q2 (L h-1 kg -1) 6.56 [13.6] 6.98 [18.6] 
𝜷𝑭,𝑭𝑶𝑹𝑴 - -0.51 [37.9] 
𝜷𝑭,𝒁𝑶𝑺𝑼 - 2.17 [7.04] 
𝜷𝒌𝒂,𝑭𝑶𝑹𝑴 - -0.713 [34.8] 
Random effects (SD) [RSE%] 
F 1.1 [13.4] 0.158 [28.1] 
ka 0.552 [20.6] 0.502 [23.2] 
V1 0.924 [13] 0.678 [15] 
CL 0.122 [35.6] 0.118 [38.8] 
Error model [RSE%] 
a 0.01 [14.1] 0.0115 [14.5] 
b 0.132 [9.34] 0.135 [10.9] 
OFV 
-2LL -665.17 -734.78 
AIC -641.17 -704.78 
Table 3: Estimated pharmacokinetic parameters after intravenous and oral administration of different doses of etoposide in wild-
type male Sprague-Dawley rats. Matrix solution consisted of 10 % (w/v) pluronic® F-127, 10% (w/v) PVP/VA, 57% (v/v) ethanol, and q.s. 
water. Individual Bayesian (post hoc) estimates were used to calculate mean AUC0-∞. Data are expressed as mean ± SEM except for tmax that 
is expressed as the median [Q1; Q3] (25% and 75% percentile). No random effects were estimated for Q and V2. Fixed effects were estimated 
as Q = 6.98 mL h-1 kg-1, V2 = 3778 mL kg
-1. Statistical significance was tested by one-way ANOVA followed by Tukey’s multiple 
comparisons test. When all the groups, except the group of rats pre-dosed with zosuquidar and the group of rats receiving i.v. administration, 
were included in the comparison, (*) referred to P < 0.05 compared to control. When all the groups, except the group of rats receiving i.v. 





Etoposide dose 20 mg kg-1 20 mg kg-1 50 mg kg-1 100 mg kg-1 20 mg kg-1 5 mg kg-1 
Condition Control    Zosuquidar  
Etoposide solution 57% EtOH Matrix Matrix Matrix 57% EtOH 57% EtOH 
Cohort Size 6 5 6 6 6 6 
Administration route p.o. p.o. p.o. p.o. p.o. i.v. 
F (%) 4.0 ± 0.13 2.4 ± 0.02* 2.4 ± 0.07* 2.2 ± 0.09* 34.5 ± 0.18† 100 ± 0 








CL (mL h-1 kg-1)  1547 ± 28 1533 ± 6.9 1503 ± 24 1587 ± 39 1550 ± 43 1636 ± 85 
V1 (mL kg-1) 3830 ± 574 4263 ± 193 4143 ± 315 4953 ± 640 2996 ± 436 809 ± 50 
AUC0-∞ (ng h mL-1) 518.8 ± 25 307.2 ± 3.5* 816.5 ± 38* 1525 ± 86* 4511 ± 384† 3096 ± 155 
AUC0-∞/D (h mL-1 kg) 25.9 ± 1.3 15.4 ± 0.2 16.3 ± 0.8 14.2 ± 0.9 225.5 ± 19.2 619.2 ± 31.0 
t½ (h) 1.73 ± 0.27 1.93 ± 0.08 1.91 ± 0.14 2.18 ± 0.31 1.36 ± 0.23 0.35 ± 0.02 
tmax (h) 0.375 [0.25-0.5] 0.625 [0.44-0.75] 0.75 [0.25-1.06] 0.75 [0.5-1.25] 0.5 [0.5-0.81] - 
Cmax (ng mL-1) 191 ± 19 63 ± 4* 169 ± 17 266 ± 38* 1542 ± 190† - 








